|
1
|
Howlader N, Noone AM, Krapcho M, Miller D,
Bishop K, Kosary CL, Yu M, Ruhl J, Tatalovich Z, Mariotto A, et al:
SEER Cancer Statistics Review (CSR), 1975–2014. Nat Cancer Inst.
(Bethesda, MD). 2017.
|
|
2
|
Curtis RE, Travis LB, Rowlings PA, Socié
G, Kingma DW, Banks PM, Jaffe ES, Sale GE, Horowitz MM, Witherspoon
RP, et al: Risk of lymphoproliferative disorders after bone marrow
transplantation: A multi-institutional study. Blood. 94:2208–2216.
1999.PubMed/NCBI
|
|
3
|
Juric MK, Ghimire S, Ogonek J, Weissinger
EM, Holler E, van Rood JJ, Oudshoorn M, Dickinson A and Greinix HT:
Milestones of hematopoietic stem cell transplantation-from first
human studies to current developments. Front Immunol. 7:4702016.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Xuan L, Huang F, Fan Z, Zhou H, Zhang X,
Yu G, Zhang Y, Liu C, Sun J and Liu Q: Effects of intensified
conditioning on Epstein-Barr virus and cytomegalovirus infections
in allogeneic hematopoietic stem cell transplantation for
hematological malignancies. J Hematol Oncol. 5:462012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Fan J, Jing M, Yang M, Xu L, Liang H,
Huang Y, Yang R, Gui G, Wang H, Gong S, et al: Herpesvirus
infections in hematopoietic stem cell transplant recipients
seropositive for human cytomegalovirus before transplantation. Int
J Infect Dis. 46:89–93. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Funke VA, Moreira MC and Vigorito AC:
Acute and chronic Graft-versus-host disease after hematopoietic
stem cell transplantation. Rev Assoc Med Bras (1992). 62 Suppl
1:S44–S50. 2016. View Article : Google Scholar
|
|
7
|
Storek J, Mohty M and Boelens JJ: Rabbit
anti-T cell globulin in allogeneic hematopoietic cell
transplantation. Biol Blood Marrow Transplant. 21:959–970. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Styczynski J, Tridello G, Gil L, Ljungman
P, Hoek J, Iacobelli S, Ward KN, Cordonnier C, Einsele H, Socie G,
et al: Impact of donor Epstein-Barr virus serostatus on the
incidence of graft-versus-host disease in patients with acute
leukemia after hematopoietic stem-cell transplantation: A study
from the acute leukemia and infectious diseases working parties of
the European society for blood and marrow transplantation. J Clin
Oncol. 34:2212–2220. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Janani MK, Malathi J, Rela M, Farouk M,
Padmapriya J and Madhavan HN: Genotypic detection of Epstein Barr
virus in pediatric transplant recipients from India. Indian
Pediatr. 52:946–950. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Styczynski J, Einsele H, Gil L and
Ljungman P: Outcome of treatment of Epstein-Barr virus-related
post-transplant lymphoproliferative disorder in hematopoietic stem
cell recipients: A comprehensive review of reported cases. Transpl
Infect Dis. 11:383–392. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Styczynski J, van der Velden W, Fox CP,
Engelhard D, de la Camara R, Cordonnier C and Ljungman P: Sixth
European Conference on Infections in Leukemia, a joint venture of
the Infectious Diseases Working Party of the European Society of
Blood and Marrow Transplantation (EBMT-IDWP), the Infectious
Diseases Group of the European Organization for Research and
Treatment of Cancer (EORTC-IDG), the International
Immunocompromised Host Society (ICHS) and the European Leukemia Net
(ELN): Management of Epstein-Barr Virus infections and
post-transplant lymphoproliferative disorders in patients after
allogeneic hematopoietic stem cell transplantation: Sixth European
Conference on Infections in Leukemia (ECIL-6) guidelines.
Haematologica. 101:803–811. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Solano C, Mateo EM, Pérez A, Talaya A,
Terol MJ, Albert E, Giménez E, Vinuesa V, Piñana JL, Boluda JCH and
Navarro D: Epstein-Barr virus DNA load kinetics analysis in
allogeneic hematopoietic stem cell transplant recipients: Is it of
any clinical usefulness? J Clin Virol. 97:26–32. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Marinho-Dias J, Lobo J, Henrique H, et al:
Post-transplant lymphoproliferative disease in hematopoietic stem
cell transplant patients: A single center retrospective study
between 2005 and 2012. Mol Med Rep (In press). 2018. View Article : Google Scholar
|
|
14
|
Marinho-Dias J and Sousa H:
Cytomegalovirus infection and cervical cancer: From past doubts to
present questions. Acta Med Port. 26:154–160. 2013.PubMed/NCBI
|
|
15
|
Henig I and Zuckerman T: Hematopoietic
stem cell transplantation-50 years of evolution and future
perspectives. Rambam Maimonides Med J. 5:e00282014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Al-Mansour Z, Nelson BP and Evens AM:
Post-transplant lymphoproliferative disease (PTLD): Risk factors,
diagnosis, and current treatment strategies. Curr Hematol Malig
Rep. 8:173–183. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Sousa H, Boutolleau D, Ribeiro J, Teixeira
AL, Pinho Vaz C, Campilho F, Branca R, Campos A Jr, Baldaque I and
Medeiros R: Cytomegalovirus infection in patients who underwent
allogeneic hematopoietic stem cell transplantation in Portugal: A
five-year retrospective review. Biol Blood Marrow Transplant.
20:1958–1967. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Campos AB, Ribeiro J, Boutolleau D and
Sousa H: Human cytomegalovirus antiviral drug resistance in
hematopoietic stem cell transplantation: Current state of the art.
Rev Med Virol. 26:161–182. 2016. View
Article : Google Scholar : PubMed/NCBI
|
|
19
|
Campos AB, Ribeiro J, Pinho Vaz C,
Campilho F, Branca R, Campos A Jr, Baldaque I, Medeiros R,
Boutolleau D and Sousa H: Genotypic resistance of cytomegalovirus
to antivirals in hematopoietic stem cell transplant recipients from
Portugal: A retrospective study. Antiviral Res. 138:86–92. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Preiksaitis JK: New developments in the
diagnosis and management of posttransplantation lymphoproliferative
disorders in solid organ transplant recipients. Clin Infect Dis.
39:1016–1023. 2004. View
Article : Google Scholar : PubMed/NCBI
|
|
21
|
Blaes AH, Cao Q, Wagner JE, Young JA,
Weisdorf DJ and Brunstein CG: Monitoring and preemptive rituximab
therapy for Epstein-Barr virus reactivation after antithymocyte
globulin containing nonmyeloablative conditioning for umbilical
cord blood transplantation. Biol Blood Marrow Transplant.
16:287–291. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
van Esser JW, van der Holt B, Meijer E,
Niesters HG, Trenschel R, Thijsen SF, van Loon AM, Frassoni F,
Bacigalupo A, Schaefer UW, et al: Epstein-Barr virus (EBV)
reactivation is a frequent event after allogeneic stem cell
transplantation (SCT) and quantitatively predicts
EBV-lymphoproliferative disease following T-cell-depleted SCT.
Blood. 98:972–978. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Dumas PY, Ruggeri A, Robin M, Crotta A,
Abraham J, Forcade E, Bay JO, Michallet M, Bertrand Y, Socié G, et
al: Incidence and risk factors of EBV reactivation after unrelated
cord blood transplantation: A Eurocord and Société Française de
Greffe de Moelle-Therapie Cellulaire collaborative study. Bone
Marrow Transplant. 48:253–256. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Reddy N, Rezvani K, Barrett AJ and Savani
BN: Strategies to prevent EBV reactivation and posttransplant
lymphoproliferative disorders (PTLD) after allogeneic stem cell
transplantation in high-risk patients. Biol Blood Marrow
Transplant. 17:591–597. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Uhlin M, Wikell H, Sundin M, Blennow O,
Maeurer M, Ringden O, Winiarski J, Ljungman P, Remberger M and
Mattsson J: Risk factors for Epstein-Barr virus-related
post-transplant lymphoproliferative disease after allogeneic
hematopoietic stem cell transplantation. Haematologica. 99:346–352.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Marques HH, Shikanai-Yasuda MA, dAzevedo
LS, Caiaffa-Filho HH, Pierrotti LC, Aquino MZ, Lopes MH, Maluf NZ,
Campos SV and Costa SF: Management of post-transplant Epstein-Barr
virus-related lymphoproliferative disease in solid organ and
hematopoietic stem cell recipients. Rev Soc Bras Med Trop.
47:543–546. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Gulley ML and Tang W: Using Epstein-Barr
viral load assays to diagnose, monitor, and prevent posttransplant
lymphoproliferative disorder. Clin Microbiol Rev. 23:350–366. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Bar-Natan M and Nagler A: Epstein-Barr
virus-associated post-transplant lymphoproliferative disorder. Isr
Med Assoc J. 8:205–207. 2006.PubMed/NCBI
|
|
29
|
Cohen J, Gandhi M, Naik P, Cubitt D, Rao
K, Thaker U, Davies EG, Gaspar HB, Amrolia PJ and Veys P: Increased
incidence of EBV-related disease following paediatric stem cell
transplantation with reduced-intensity conditioning. Br J Haematol.
129:229–239. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
van Esser JW, Niesters HG, van der Holt B,
Meijer E, Osterhaus AD, Gratama JW, Verdonck LF, Löwenberg B and
Cornelissen JJ: Prevention of Epstein-Barr
virus-lymphoproliferative disease by molecular monitoring and
preemptive rituximab in high-risk patients after allogeneic stem
cell transplantation. Blood. 99:4364–4369. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Dabas R, Lee R, Servito MT, Dharmani-Khan
P, Modi M, van Slyke T, Luider J, Durand C, Larratt L, Brandwein J,
et al: Antithymocyte globulin at clinically relevant concentrations
kills leukemic blasts. Biol Blood Marrow Transplant. 22:815–824.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Crocchiolo R, Esterni B, Castagna L, Fürst
S, El-Cheikh J, Devillier R, Granata A, Oudin C, Calmels B,
Chabannon C, et al: Two days of antithymocyte globulin are
associated with a reduced incidence of acute and chronic
graft-versus-host disease in reduced-intensity conditioning
transplantation for hematologic diseases. Cancer. 119:986–992.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Bacigalupo A: ATG in allogeneic stem cell
transplantation: Standard of care in 2017? Point? Blood Adv.
1:569–572. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Pidala J, Tomblyn M, Nishihori T, Ayala E,
Field T, Fernandez H, Perez L, Locke F, Alsina M, Ochoa JL, et al:
ATG prevents severe acute graft-versus-host disease in mismatched
unrelated donor hematopoietic cell transplantation. Biol Blood
Marrow Transplant. 17:1237–1244. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Podgorny PJ, Ugarte-Torres A, Liu Y,
Williamson TS, Russell JA and Storek J: High rabbit-antihuman
thymocyte globulin levels are associated with low likelihood of
graft-vs-host disease and high likelihood of posttransplant
lymphoproliferative disorder. Biol Blood Marrow Transplant.
16:915–926. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Janeczko M, Mielcarek M, Rybka B,
Ryczan-Krawczyk R, Noworolska-Sauren D and Kałwak K: Immune
recovery and the risk of CMV/EBV reactivation in children post
allogeneic haematopoietic stem cell transplantation. Cent Eur J
Immunol. 41:287–296. 2016. View Article : Google Scholar : PubMed/NCBI
|
